DMNT inhibitors such as zebularine have been shown to reexpress RASSF1A and increase the radiosensitivity of these cancers suggesting that reexpression of RASSF1A and other silenced RASSFs maybe a path through which chemoradioresistant tumours can be combated. This evidence concerns the gene RASSF1 and neoplasm.